HighGravityDataCardinal Health — May 1, 2025 release
Fiscal 2025 third-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000721371-25-000036
Showing in the filing
Global Medical Products and Distribution segment profit
“at least consistent with fiscal 2025 segment profit”
Period
FY2026
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 9
Non-GAAP diluted earnings per share attribut… for FY2025
“$8.05 to $8.15”
Pharmaceutical and Specialty Solutions segme… for FY2025
“11.5% to 12.5% growth”
Other segment profit growth outlook for FY2025
“16% to 18% growth”
GMPD segment profit outlook for FY2025
“$130 million to $140 million”
Interest and other expense outlook for FY2025
“$200 million to $215 million”
Non-GAAP effective tax rate outlook for FY2025
“23% to 23.5%”
Diluted weighted average shares outstanding … for FY2025
“~242 million”
Global Medical Products and Distribution seg… for FY2026
“at least consistent with fiscal 2025 segment profit”
GMPD segment profit expectation for FY2026
“at least consistent with fiscal 2025 segment profit”
Exhibit 99.1 · the passage around this item
… earlier in the release
The company continues to expect strong segment profit growth in Pharmaceutical and Specialty Solutions and across its three operating segments reported in Other. In the face of the macro uncertainty, the company is updating its expectations for fiscal 2026 GMPD segment profit, which it now expects to be at least consistent with fiscal 2025 segment profit. The company will continue to assess opportunities and risks and plans to further discuss its expectations for fiscal 2026 and beyond at its upcoming Investor Day on June 12, 2025. Recent highlights • GI Alliance bolstered its leading multi-specialty MSO platform by entering into the urology therapeutic area with agreements to acquire Urology America and Potomac Urology, furthering its strategy to support physician-led practices and deliver superior patient outcomes • Cardinal Health completed its acquisition of Advanced Diabetes Supply Group on April 1 st . ADSG is a leading national direct-to-patient diabetes medical supplies provider that enhances at-Home Solutions’ capabilities to service patients in their homes • Cardinal Health elected two new independent directors with extensive leadership experience to its board of directors: Robert Musslewhite, former CEO of Definitive Healthcare Corp. and Sudhakar Ramakrishna, President and CEO of SolarWinds Corporation • Cardinal Health completed a $375M accelerated share repurchase program during the third quarter • Cardinal Health announced that it has entered into an agreement with GE Healthcare to manufacture and distribute Flyrcado
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.